Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus RENOGRAFIN 76.
DIONOSIL AQUEOUS vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent